Helmet Based Ventilation Allows Higher PEEP With Minimal Leaks in ARDS, New Intensive Care Medicine Review Finds
Aurika Savickaite
10/14/2026 Chicago
A new review in Intensive Care Medicine by Laveena Munshi, Massimo Antonelli and Jean-Pierre Frat finds that helmet non-invasive ventilation (NIV) lets clinicians deliver higher positive end-expiratory pressure (PEEP) "with minimal air leaks" in patients with acute respiratory distress syndrome (ARDS).
The review, "Non-invasive respiratory supports in ARDS: Physiology-guided use, pitfalls, and pathways to success," was published on October 7, 2026. It looks at NIV, continuous positive airway pressure (CPAP) and high-flow nasal cannula (HFNC) in ARDS and acute hypoxemic respiratory failure, not only in COVID-19.
Why it matters
Non-invasive support is now used much more often than before. In the pre-COVID LUNG SAFE study, NIV was used in only about 15% of patients with ARDS, the authors note.
Today, evidence for HFNC and helmet NIV keeps growing, and the 2024 Global Definition of ARDS now recognizes patients supported without a breathing tube.
The goal is to avoid the complications of invasive mechanical ventilation. But the authors warn that strong, uncontrolled breathing effort can injure the lungs, called patient self-inflicted lung injury (P-SILI).
What the review found about helmets
The authors list several physiological advantages of the helmet interface:
Higher PEEP with minimal leaks. "Helmet NIV enables the delivery of higher PEEP levels with minimal air leaks."
Asynchronies matter less. Patient–ventilator asynchronies "are generally less clinically relevant than with face masks." Even when an effort does not trigger pressure support, the patient still draws air from the helmet, so it is real work of breathing.
A possible lung-protective effect. The authors describe a hypothesis that the helmet's longer trigger delays and less efficient pressurization may limit excessive transpulmonary pressure swings and "potentially" enhance lung protection. This is a hypothesis, not a proven effect.
No mask seal problems. Face masks can be hard to seal in patients without teeth, with beards, or with nasogastric tubes. "These inconveniences are minimized with the Helmet interface," the authors write.
Fewer intubations than HFNC in COVID-19. Helmet NIV reduced intubation compared with HFNC in patients with COVID-19, citing the study by D.L. Grieco and colleagues in JAMA (2021).
Starting settings
The review suggests reasonable initial NIV/CPAP settings:
PEEP of about 5 cm H2O, up to 10 cm H2O.
Pressure support of 5–8 cm H2O above PEEP.
With the helmet, patients with persistent hypoxemia may need higher PEEP of 8 to 12 cm H2O.
Settings should then be quickly adjusted to patient comfort, breathing effort, tidal volume, oxygenation and gas exchange.
Where HFNC fits
The authors recommend HFNC as first-line non-invasive support for most patients with moderate ARDS, because it can reduce intubation rates. They suggest starting at 40–60 L/min, typically 50 L/min.
NIV or CPAP may help carefully selected patients with mild ARDS, without hemodynamic instability and with normal mental status.
They state there is not enough evidence to support or reject NIV and CPAP as first-line therapy in ARDS. Both should be used as "time-limited, closely monitored physiological trials," with special caution when PaO2/FiO2 is below 150 mmHg.
Knowing when to intubate
Delayed intubation is linked to higher mortality in several studies. The review cites French recommendations listing two major criteria for intubation: cardiac or respiratory arrest due to hypoxemia, and persistent hypoxemia despite maximal oxygen support (PaO2/FiO2 below 60 mmHg and/or SpO2 below 88%).
For HFNC, the ROX index (SpO2/FiO2 divided by respiratory rate) is the best-validated bedside tool for predicting failure, but it should complement clinical judgment, not replace it.
Limitations and what is still unknown
The review is honest about the helmet's challenges. With the helmet, "it remains challenging to monitor tidal volumes," which matters because large tidal volumes (more than 9 mL/kg predicted body weight) have been linked to poor outcomes.
The authors also note the helmet "may be associated with claustrophobia."
Evidence for NIV and CPAP in ARDS is still inconsistent. Much of it comes from older studies of acute hypoxemic respiratory failure, using earlier ARDS definitions. Ongoing randomized trials, HENIVOT-2 (NCT05089695), HighCPAP (NCT06213168) and HONOUR (NCT05078034), are expected to clarify the role of these approaches.
A nurse's perspective
"In my experience, claustrophobia with the helmet is less common than people expect. Nothing touches the patient's face, the helmet is transparent, and there is a constant airflow inside. Patients can see their nurses and family, talk, and look around. When we explain it well before we put it on, most patients settle in quickly," said Aurika Savickaite, MSN, RN, founder of helmetbasedventilation.com.
More studies are needed to define which ARDS patients benefit most from helmet NIV and how best to set and monitor it.
To learn how to apply helmets safely and effectively, take our free online course, and subscribe to our newsletter for the latest research.
Reference
Munshi L, Antonelli M, Frat JP. Non-invasive respiratory supports in ARDS: Physiology-guided use, pitfalls, and pathways to success. Intensive Care Med. Published online October 7, 2026. https://doi.org/10.1007/s00134-026-08616-x
Grieco DL, Menga LS, Cesarano M, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure. JAMA. 2021;325(17):1731-1743. https://doi.org/10.1001/jama.2021.4682
Tags: ARDS, Helmet NIV, PEEP, HFNC, Intubation, Research, For Doctors
Comments